+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia



Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia



Leukemia and Lymphoma 51(7): 1233-1240



Statins and non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed medications. In vitro studies suggest that statins and NSAIDs may have potential as anticancer therapies in low-grade non-Hodgkin lymphomas including chronic lymphocytic leukemia (CLL), and a recent observational study found statin use was associated with improved event free survival in patients with follicular lymphoma. Other studies have suggested that statins reduce the efficacy of rituximab by inhibiting binding to CD20. We therefore conducted an observational cohort study of 686 patients with newly diagnosed Rai stage 0 CLL to evaluate whether statin or NSAID use was related to their clinical outcome or influenced the efficacy of rituximab therapy. At diagnosis, 136 (20%) patients took statins and 230 (34%) scheduled daily aspirin, ibuprofen, or naproxen. No difference in time to treatment was observed based on statin or NSAID use. Among patients receiving a rituximab-containing first-line therapy, no difference in time to salvage treatment was observed based on statin use. Although previous studies suggested statins may improve event free survival among patients with follicular lymphoma, we find no impact of statins on time to initial therapy in this large study of patients with Rai stage 0 CLL. The in vitro observation that statins reduce rituximab efficacy does not appear to have clinical significance in CLL care.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911053

Download citation: RISBibTeXText

PMID: 20496995

DOI: 10.3109/10428194.2010.486877


Related references

Non-steroidal anti-inflammatory drug therapy for chronic lymphocytic leukemia. Leukemia and Lymphoma 47(12): 2445-2446, 2006

Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia. Leukemia Research 57: 65-71, 2017

Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood 75(7): 1414-1421, 1990

A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood 75(7): 1422-1425, 1990

CHOP regimen versus intermittent chlorambucil-prednisone in stage B chronic lymphocytic leukemia. Short term results from a randomized clinical trial. French Cooperative Group on Chronic Lymphocytic Leukemia. Nouvelle Revue Francaise D'hematologie 30(5-6): 449-452, 1988

Reduced t colony forming capacity in b chronic lymphocytic leukemia 2. correlation with clinical stage and findings in b pro lymphocytic leukemia. Leukemia Research 6(3): 329-334, 1982

Upper aerodigestive tract cancer in patients with chronic lymphocytic leukemia: incidence, stage, and outcome. Archives of Otolaryngology--Head and Neck Surgery 138(12): 1171-1175, 2014

Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. Blood 123(9): 1424-1426, 2014

The influence of non-steroidal anti-inflammatory drugs on clinical outcome in patients with bleeding peptic ulcers. Korean Journal of Gastroenterology 46(5): 373-380, 2005

Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome. Haematologica 90(4): 465-469, 2005

A clinical investigation of the mechanism of loxoprofen, a non-steroidal anti-inflammatory drug, for patients with nocturia. Acta Medica Okayama 62(6): 373-378, 2009

Clinical pharmacology of GP53,633--a new non-steroidal anti-inflammatory drug--in patients with rheumatoid arthritis. Agents and Actions 15(3-4): 424-427, 1984

Polymorphisms of TNF and IL-10 genes and clinical outcome of patients with chronic lymphocytic leukemia. Genes, Chromosomes and Cancer 52(3): 287-296, 2013

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. Journal of Clinical Oncology 32(19): 2067-2073, 2014

High levels of CD160 expression up-regulated counts of chronic lymphocytic leukemia cells and were associated with other clinical parameters in Chinese patients with chronic lymphocytic leukemia. Leukemia and Lymphoma 56(2): 529-532, 2016